Market Outlook Snapshot Market Dynamics Regional Forecast Country Insights Segment Analysis Competitive Landscape Industry News report.faq_name
On This Report

CyberKnife Market Size & Growth Forecast 2026–2035, By Segments (End-use, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Report ID: FBI 11171| Published Date: Mar-2026| Format: PDF, Excel
MARKET OUTLOOK

Market Size and Growoth Outlook

CyberKnife Market size was assessed at USD 720.03 Million in 2025 and is poised to grow at a 17.4% CAGR between 2026 and 2035, attaining USD 3.58 Billion by 2035. The industry revenue for 2026 is calculated at USD 831.54 million.

Base Year Value (2025)
USD 720.03 Million
CAGR (2026-2035)
17.4%
Forecast Year Value (2035)
USD 3.58 Billion
Historical Data Period
2022-2025
Largest Region
North America
Forecast Period
2026-2035

Get more details on this report

Request Free Sample Report
SNAPSHOT

CyberKnife Market Intelligence Snapshot

Regional Market Dynamics

  • North America leads with 43.99% share due to advanced radiation oncology infrastructure, high system integration in cancer care, and strong concentration of specialized treatment centers and clinicians.
  • Asia Pacific grows at 19.49% CAGR driven by expanding oncology facilities, rising cancer care investments, and increasing use of non-invasive radiosurgery in urban healthcare networks.

Segment Momentum

  • Hospitals lead with 53.76% share due to strong multidisciplinary oncology infrastructure, advanced imaging systems, and referral networks supporting complex radiosurgery and high-acuity patient management across treatment pathways.
  • Vascular malformation is the fastest-growing application as CyberKnife enables precise, non-invasive targeting of sensitive vascular structures, supporting safer treatment options where conventional interventions are more complex.

Market Expansion Drivers

  • Increasing global cancer prevalence accelerating demand for non-invasive robotic radiosurgery treatments.
  • Technological advancements and new CyberKnife system launches improving treatment precision and efficiency.
  • Growing preference for minimally invasive oncology procedures expanding hospital adoption of CyberKnife systems.

Leading Market Participants

FORECAST SNAPSHOT

Global Market Forecast Snapshot

Market Outlook

Prominent companies in the CyberKnife market include Accuray Incorporated (United States), Elekta AB (Sweden), Varian Medical Systems, Inc. (United States), Siemens Healthineers AG (Germany), United Imaging Healthcare Co., Ltd. (China), ViewRay Technologies, Inc. (United States), Brainlab AG (Germany), Hitachi, Ltd. (Japan), RaySearch Laboratories AB (Sweden).

Regional and Segment Outlook

North America
MARKET DYNAMICS

Market Growth Drivers and Industry Trends

Increasing global cancer prevalence accelerating demand for non-invasive robotic radiosurgery treatments

Rising cancer incidence is pushing providers to expand treatment capacity without proportionally increasing surgical burden, which is increasing demand for the CyberKnife market as hospitals and cancer centers seek non-invasive options for patients who are inoperable, medically fragile, or unsuitable for conventional radiation approaches. CyberKnife systems fit this need by enabling highly targeted radiosurgery for tumors in sensitive or hard-to-reach locations, allowing institutions to treat a broader case mix while reducing dependence on operating room time and extended inpatient recovery. As oncology departments face growing patient volumes, this practical ability to deliver precise outpatient treatment is reinforcing market demand and shaping capital investment decisions in advanced radiation platforms.

Technological advancements and new CyberKnife system launches improving treatment precision and efficiency

Ongoing innovation in imaging, motion tracking, treatment planning, and workflow design is supporting market development in the CyberKnife market by making the platform more clinically attractive and operationally viable for radiation oncology centers. Improvements in precision support treatment of moving tumors and complex anatomies with greater confidence, which directly influences physician adoption and referral patterns in indications where tissue preservation and dose accuracy matter most. At the same time, newer system launches that streamline setup, planning, and delivery help facilities improve throughput and resource utilization, making high-end radiosurgery easier to justify in budget and procurement decisions.

Growing preference for minimally invasive oncology procedures expanding hospital adoption of CyberKnife systems

A clear shift toward minimally invasive cancer care is increasing market penetration in the CyberKnife market because hospitals are under pressure to offer effective treatment pathways that reduce procedural risk, shorten recovery time, and align with patient preference for less disruptive interventions. CyberKnife supports this transition by providing a non-surgical option that can be integrated into multidisciplinary oncology programs for selected tumors, helping providers retain patients who might otherwise be referred for alternative advanced radiation or surgical care elsewhere. This changes adoption behavior at the hospital level, where investment in robotic radiosurgery is increasingly tied to service-line competitiveness, patient experience goals, and the need to broaden precision oncology offerings without expanding surgical infrastructure.

Growth Driver Impact on CAGR Regulatory Influence Geographic Relevance Adoption Rate Impact Timeline
Increasing global cancer prevalence accelerating demand for non-invasive robotic radiosurgery treatments 2.20% High North America, Asia Pacific High Near Term
Technological advancements and new CyberKnife system launches improving treatment precision and efficiency 1.80% High North America, Europe High Mid Term
Growing preference for minimally invasive oncology procedures expanding hospital adoption of CyberKnife systems 1.50% Moderate Asia Pacific, Latin America Medium Mid Term
CUSTOM RESEARCH

Unlock insights tailored to your business with our bespoke market research solutions.

Click to get your customized report now.

Request Customization →
REGIONAL FORECAST

Regional Demand Dynamics

Polymer Modified Bitumen Market
Largest Region
North America
43.99% Market Share in 2025
North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the leading regional share of the CyberKnife market in 2025, accounting for 43.99% share, bolstered by its established radiation oncology infrastructure and broader integration of advanced radiosurgery systems into hospital and specialty cancer care settings. The region’s leadership is sustained by the practical ability of providers to deploy CyberKnife platforms within mature clinical workflows, where precision treatment for tumors in difficult anatomical locations aligns with demand for non-invasive care. Market activity is further strengthened by the concentration of specialized treatment centers, experienced clinicians, and patient access to high-end oncology procedures, which together support consistent system utilization and replacement-driven demand.

Asia Pacific is projected to expand at a 19.49% CAGR over the forecast period, with the CyberKnife market gaining momentum as cancer care capacity broadens and providers invest in advanced treatment technologies to address rising patient volumes. Growth is being fueled by the gradual buildout of specialized oncology facilities and increasing adoption of precise, non-invasive radiosurgery in urban healthcare networks where providers are seeking differentiated treatment capabilities. As access to advanced cancer treatment improves across key markets in the region, adoption is accelerating in practice through new installations, expanding clinical use, and stronger alignment between technology investment and unmet treatment demand.

Parameter North America Asia Pacific Europe Latin America MEA
Innovation Hub i Scale Nascent Developing Advanced
Cost-Sensitive Region i Scale Low Medium High
Regulatory Environment i Scale Restrictive Neutral Supportive
Demand Drivers i Scale Weak Moderate Strong
Development Stage i Scale Emerging Developing Developed
Adoption Rate i Scale Low Medium High
New Entrants/Startups i Scale Low Medium High
Macro Indicators i Scale Weak Stable Strong
COUNTRY INSIGHTS

Key Country Insights

Germany 🇩🇪

Precision Oncology Integration

Germany incorporates CyberKnife systems into specialized cancer treatment centers with a strong emphasis on precision radiation therapy. Healthcare providers focus on expanding access to highly targeted treatment approaches while optimizing clinical efficiency and patient outcomes.

France 🇫🇷

Multidisciplinary Oncology Services

France supports the CyberKnife market through coordinated oncology programs that integrate advanced radiosurgery with broader cancer treatment strategies. Clinical priorities include accurate tumor targeting, reduced treatment burden, and collaborative care planning across specialized medical teams.

Italy 🇮🇹

Hospital Technology Modernization

Italy continues incorporating CyberKnife technology into tertiary care hospitals as part of broader oncology service modernization. Healthcare institutions prioritize precision treatment capabilities, multidisciplinary clinical collaboration, and expanded availability of non-invasive therapeutic options for complex cancer cases.

Japan 🇯🇵

Specialized Cancer Care

Japan utilizes CyberKnife technology to support minimally invasive treatment for complex neurological and oncological conditions. Hospitals in Japan emphasize treatment precision, patient comfort, and integration of advanced radiosurgery into comprehensive cancer care pathways.

South Korea 🇰🇷

Technology-Enabled Treatment Centers

South Korea continues strengthening the CyberKnife market through investment in advanced oncology infrastructure and specialized treatment facilities. Healthcare providers emphasize precision therapy, efficient treatment planning, and expanded access to innovative radiation technologies for appropriate patient populations.

United States 🇺🇸

Advanced Radiosurgery Adoption

The U.S. CyberKnife market benefits from broad adoption of precision radiosurgery for complex oncology treatments across major healthcare institutions. Providers in the U.S. prioritize non-invasive treatment options, multidisciplinary cancer care, and technology upgrades that improve clinical workflow and treatment accuracy.

SEGMENT ANALYSIS

Segment Leadership and Growth Trends

CyberKnife Market Share (%), End-use, 2025

Hospitals
Outpatient Facilities
Research & Manufacturing

Go beyond the chart, access full insights & data tables

Request Free Sample Report
End-use Segment Analysis: Hospitals (Largest Segment) vs Outpatient Facilities (Fastest-Growing Segment)

Hospitals held a 53.76% share of the CyberKnife market in 2025, reflecting their established role as the primary setting for complex radiosurgery procedures. This leadership is underpinned by hospitals’ ability to support multidisciplinary treatment planning, advanced imaging integration, and the clinical infrastructure required for high-acuity oncology and neurological cases. In the CyberKnife market, hospitals also benefit from stronger referral networks and the operational capacity to manage patients who need coordinated care before, during, and after treatment.

Outpatient Facilities are emerging as the fastest-growing end-use segment in the CyberKnife market as providers increasingly look for efficient treatment settings that can handle precision, non-invasive procedures without the cost structure of large hospital systems. Their momentum is backed by the practical fit between CyberKnife treatment delivery and outpatient care models, especially where shorter recovery needs and streamlined patient throughput are becoming more valuable. Compared with hospitals, outpatient facilities are gaining traction because they align more directly with the shift toward convenient, lower-burden care delivery for suitable cases.

Application Segment Analysis: Cancer (Largest Segment) vs Vascular Malformation (Fastest-Growing Segment)

Within the CyberKnife market, Cancer accounted for a 46.43% share in 2025, making it the leading application segment. Its position is anchored in the broad clinical use of robotic radiosurgery across multiple tumor types where precision targeting is essential and treatment must limit exposure to surrounding healthy tissue. Cancer continues to lead the CyberKnife market because the installed clinical workflows, physician familiarity, and patient demand are concentrated most heavily around oncology use, giving this application a durable base of procedural volume.

Vascular Malformation is the fastest-growing application in the CyberKnife market, influenced by increasing use of highly precise, non-invasive treatment approaches for cases that require careful management around sensitive vascular structures. Its growth relative to other applications is backed by the practical advantage of CyberKnife systems in delivering focused radiation where conventional intervention may be more complex or less suitable. As treatment teams expand the use of radiosurgery beyond established oncology pathways, vascular malformation is gaining momentum through this clear procedural fit.

Segment Sub-Segment Largest Segment Fastest Growing
End-use Hospitals, Outpatient Facilities, Research & Manufacturing Hospitals Outpatient Facilities
Application Tumor, Cancer, Vascular Malformation, Others Cancer Vascular Malformation
Competitive Landscape

Competitive Landscape and Market Positioning

Prominent players in the CyberKnife market:

1. Accuray Incorporated (United States)

2. Elekta AB (Sweden)

3. Varian Medical Systems Inc. (United States)

4. Siemens Healthineers AG (Germany)

5. United Imaging Healthcare Co. Ltd. (China)

6. ViewRay Technologies Inc. (United States)

7. Brainlab AG (Germany)

8. Hitachi Ltd. (Japan)

9. RaySearch Laboratories AB (Sweden)

The CyberKnife market is witnessing increasing emphasis on precision-focused cancer treatment technologies and non-invasive therapeutic solutions. Industry participants are integrating advanced imaging systems, robotic targeting capabilities, and treatment planning software to improve clinical accuracy and patient outcomes. Continuous research activity and technological refinement aimed at expanding treatment applications are further strengthening innovation within the radiotherapy landscape.

Company Market Share Company Revenue Revenue CAGR (%) Product Portfolio Geographic Presence Innovation / R&D Focus Strategic Developments
No companies available.
🔒 This section is available as a standalone purchase. Buy only the data you need. Inquire Before Buying
Industry News

Industry Development/News

Company Name Date Key Development
Asian Hospital Inc. Mar-26 Asian Hospital received Board of Investments approval for a dedicated robotic treatment facility to house its CyberKnife radiotherapy service. This infrastructure investment significantly bolsters the facility's precision oncology capabilities and expands clinical access to stereotactic radiosurgery-based cancer treatments within the region.
Accuray Incorporated Jan-25 Accuray Incorporated secured approval from China’s National Medical Products Administration for its Radixact SynC and CyberKnife S7 systems. This regulatory milestone enables the company to expand its installed base and commercial footprint in the high-growth Chinese radiotherapy market, facilitating broader access to advanced, robotic-assisted cancer treatment technologies.
SEHA Nov-25 SEHA successfully commissioned the first CyberKnife installation at Tawam Hospital in Abu Dhabi. This deployment represents a critical enhancement to the UAE's advanced oncology infrastructure, enabling high-precision, non-invasive radiation delivery for complex cancer cases and establishing a new standard for stereotactic radiosurgery within the regional healthcare system.
Asian Hospital and Medical Center Sep-25 Asian Hospital integrated CyberKnife-based radiotherapy technology with real-time tumor tracking capabilities into its oncology department. By enabling adaptive, non-invasive radiation delivery, the system improves treatment precision for diverse tumor types, reflecting the broader clinical shift toward automated, image-guided stereotactic radiosurgery in oncology workflows.
HCG Cancer Centre Sep-24 HCG Cancer Centre commissioned an AI-driven CyberKnife S7 system, leveraging real-time motion adaptation and automated delivery protocols. This technological adoption marks a significant advancement in robotic radiosurgery, providing improved operational efficiency and clinical precision for both malignant and non-malignant tumor treatments compared to legacy radiotherapy systems.
Kenyatta University Teaching, Referral, and Research Hospital Sep-23 The commissioning of a CyberKnife radiotherapy system at Kenyatta University Teaching, Referral, and Research Hospital represents a landmark development as the first such system in Sub-Saharan Africa. This infrastructure investment serves to bridge a major technological gap in regional oncology, significantly expanding access to high-precision, non-invasive cancer care.
Heidelberg University Hospital Jun-24 Heidelberg University Hospital integrated the Radixact System into its radiotherapy department, augmenting its cancer treatment portfolio with advanced technology from Accuray Incorporated. This procurement demonstrates the ongoing adoption of sophisticated, automated radiation therapy platforms in leading European academic medical centers, aimed at enhancing personalized treatment precision and patient outcomes.
Report Customization

Explore This Report

Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.

1 report.custom report.segments 2 Custom TOC 3 Related Reports

CyberKnife Market — Custom Segments

Segment Sub-Segment
No segment data available.

CyberKnife Market — report.custom

Custom Chapter Custom Details
No custom TOC data available.

Need a different cut of the data?

Request Custom Research
report.faq_name

What is the market size of CyberKnife?

In 2026 the market for CyberKnife is valued at USD 831.54 million.

How is the CyberKnife industry projected to perform over the next decade?

CyberKnife Market size is set to grow from USD 720.03 million in 2025 to USD 3.58 billion by 2035 reflecting a CAGR greater than 17.4% through 2026-2035.

How is rising cancer prevalence influencing hospital investment and treatment capacity planning in the CyberKnife market?

Increasing cancer incidence is driving demand for non-invasive robotic radiosurgery that can treat complex or inoperable tumors while reducing surgical burden. Hospitals are investing in CyberKnife systems to expand outpatient treatment capacity and manage higher patient volumes efficiently.

How are technological improvements and minimally invasive care trends shaping adoption of CyberKnife systems?

Advances in imaging, motion tracking, and workflow efficiency are improving treatment precision and throughput, while the shift toward minimally invasive oncology is increasing hospital preference for CyberKnife as a competitive, patient-friendly radiation therapy option.

Why do hospitals hold the largest share in the CyberKnife market?

Hospitals lead with 53.76% share due to strong multidisciplinary oncology infrastructure, advanced imaging systems, and referral networks supporting complex radiosurgery and high-acuity patient management across treatment pathways.

What is driving growth in vascular malformation applications?

Vascular malformation is the fastest-growing application as CyberKnife enables precise, non-invasive targeting of sensitive vascular structures, supporting safer treatment options where conventional interventions are more complex.

Why does North America lead the CyberKnife market?

North America leads with 43.99% share due to advanced radiation oncology infrastructure, high system integration in cancer care, and strong concentration of specialized treatment centers and clinicians.

What is driving CyberKnife adoption in Asia Pacific?

Asia Pacific grows at 19.49% CAGR driven by expanding oncology facilities, rising cancer care investments, and increasing use of non-invasive radiosurgery in urban healthcare networks.

Which organizations are considered leaders in the CyberKnife landscape?

Prominent companies in the CyberKnife market include Accuray Incorporated (United States), Elekta AB (Sweden), Varian Medical Systems, Inc. (United States), Siemens Healthineers AG (Germany), United Imaging Healthcare Co., Ltd. (China), ViewRay Technologies, Inc. (United States), Brainlab AG (Germany), Hitachi, Ltd. (Japan), RaySearch Laboratories AB (Sweden).
Testimonials

Our Clients

"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."

Quality Assurance Manager

"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."

R&D Manager

"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."

Senior Marketing Manager
THE RESEARCH BEHIND THIS REPORT

Our Research Team & Methodology

Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.

THIS REPORT'S RESEARCH VERTICAL

Research Team Overview

♢
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.

Prepared by the Healthcare & Medical Devices Research Team

10+
Industry Verticals
100+
Countries Analyzed
5–7
Days Standard
Delivery
12k+
Research Reports
Published
On-
Demand
Customized Research
Available
6
Months Analyst
Support
PDF + XLS
Report Deliverables

Trust & Compliance

☷D&B D-U-N-S
♢GDPR & CCPA Compliant
♙ISO 9001 Certified (ISO 9001:2015)
♙SSL Encryption
▭Secure Payments
✓Confidential Handling

Research Domains

10 coverage areas
Medical Devices & Equipment Diagnostic Imaging Clinical Diagnostics Digital Health & Telemedicine Patient Monitoring Systems Surgical & Minimally Invasive Technologies Healthcare IT & Data Systems Biotechnology & Life Sciences Pharmaceutical Technologies Healthcare Delivery & Services

Research Intelligence

Executive Leadership
Product & Technology Experts
Manufacturing & Operations Leaders
Procurement & Supply Chain Professionals
Sales & Commercial Executives
Channel Partners & Distribution Networks
Enterprise Buyers & End Users
Industry Consultants & Regulatory Experts

Research Workflow & Quality Assurance

📥
01

Data Collection

Verified information gathered through primary and secondary research.

🔍
02

Data Triangulation

Cross-validation using multiple independent data sources.

📈
03

Forecast Modelling

Market estimates developed using historical trends and analytical models.

👨‍💼
04

Analyst Validation

Findings reviewed by domain experts for accuracy and consistency.

📝
05

Editorial & Quality Review

Final editorial, quality, and compliance checks before publication.

✅
06

Final Publication

Released after successful completion of the internal review process.

Report Coverage

📊 Market Assessment

  • Market Size & Forecast
  • Market Segmentation
  • Regional Analysis
  • Growth Drivers & Challenges
  • Market Dynamics

🏢 Competitive Intelligence

  • Competitive Landscape
  • Company Profiles
  • Competitive Benchmarking
  • Mergers & Acquisitions
  • Market Share Analysis or Key Company Strategies

🔍 Strategic Analysis

  • Value Chain Analysis
  • Porter's Five Forces
  • PESTLE Analysis
  • Pricing Trends
  • Supply-Demand Analysis

🚀 Future Outlook

  • Technology Landscape
  • Regulatory Landscape
  • Investment & Funding Landscape
  • Emerging Opportunities
  • Future Market Outlook

Have a question about this report or need a custom scope?

Request Customization
License

Select License Type

Single User
US$ 4,250
Buy Now
Corporate User
US$ 6,150
Buy Now

Want this data scoped to your exact question?

Tell us the segments, regions, or competitors you need answered — an analyst will confirm scope before any custom work starts.

Talk to an Analyst →